ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
+12.23%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$597M
AUM Growth
+$99.9M
(+20%)
Cap. Flow
+$40.6M
Cap. Flow
% of AUM
6.81%
Top 10 Holdings %
Top 10 Hldgs %
54.95%
Holding
336
New
84
Increased
77
Reduced
72
Closed
71
Top Buys
| 1 |
Immunovant
IMVT
|
$18.7M |
| 2 |
Ascendis Pharma
ASND
|
$16.4M |
| 3 |
Zura Bio
ZURA
|
$15.3M |
| 4 |
Zai Lab
ZLAB
|
$12.3M |
| 5 |
AAM
AA Mission Acquisition Corp.
AAM
|
$10.1M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$28M |
| 2 |
Roivant Sciences
ROIV
|
$13M |
| 3 |
Edgewise Therapeutics
EWTX
|
$11.2M |
| 4 |
Merck
MRK
|
$8.47M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$6.96M |
Sector Composition
| 1 | Healthcare | 88.63% |
| 2 | Financials | 3.75% |
| 3 | Communication Services | 0.59% |
| 4 | Utilities | 0.21% |
| 5 | Technology | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
10x Genomics
TXG
$1.74B
| $339K | 0.06% |
+15,000
| New | +$339K |
|
127
RenovoRx
RNXT
$45.1M
| $334K | 0.05% |
315,192
-40,048
| -11% | -$42.5K |
|
128
Oak Woods Acquisition Corp
OAKU
| $333K | 0.05% |
30,000
| – | – |
|
129
Arcellx
ACLX
$4.02B
| $331K | 0.05% |
3,962
+3,862
| +3,862% | +$323K |
|
130
PolyPid
PYPD
$55M
| $323K | 0.05% |
93,902
-10,048
| -10% | -$34.6K |
|
|
JVSA
131
DELISTED
JV SPAC Acquisition Corp
JVSA
| $310K | 0.05% |
+30,000
| New | +$310K |
|
132
AbCellera Biologics
ABCL
$1.25B
| $299K | 0.05% |
+114,981
| New | +$299K |
|
133
Jasper Therapeutics
JSPR
$44.7M
| $297K | 0.05% |
+15,816
| New | +$297K |
|
134
Tourmaline Bio
TRML
$695M
| $289K | 0.05% |
11,260
-9,800
| -47% | -$252K |
|
|
VRNA
135
Verona Pharma
VRNA
$9.2B
| $288K | 0.05% |
+10,000
| New | +$288K |
|
136
VYNE Therapeutics
VYNE
$7.59M
| $287K | 0.05% |
152,865
-18,352
| -11% | -$34.5K |
|
137
Delcath Systems
DCTH
$409M
| $280K | 0.05% |
31,052
-167,295
| -84% | -$1.51M |
|
|
ORKA
138
Oruka Therapeutics, Inc. Common Stock
ORKA
$615M
| $274K | 0.04% |
11,187
+4,131
| +59% | +$101K |
|
139
BioCryst Pharmaceuticals
BCRX
$1.74B
| $266K | 0.04% |
35,000
+5,600
| +19% | +$42.6K |
|
140
Insmed
INSM
$30.6B
| $265K | 0.04% |
3,634
-38,583
| -91% | -$2.82M |
|
|
SLRN
141
DELISTED
ACELYRIN
SLRN
| $264K | 0.04% |
53,500
+2,979
| +6% | +$14.7K |
|
142
Iron Horse Acquisitions Corp
IROH
$22.1M
| $255K | 0.04% |
+25,000
| New | +$255K |
|
143
Voyager Therapeutics
VYGR
$234M
| $238K | 0.04% |
40,634
+22,000
| +118% | +$129K |
|
|
JBIO
144
Jade Biosciences, Inc. Common Stock
JBIO
$252M
| $236K | 0.04% |
3,231
-3,824
| -54% | -$280K |
|
145
Arrowhead Research
ARWR
$4B
| $227K | 0.04% |
11,705
+5,805
| +98% | +$112K |
|
|
CMRX
146
DELISTED
Chimerix, Inc.
CMRX
| $224K | 0.04% |
240,557
+62,328
| +35% | +$58K |
|
|
ONC
147
BeOne Medicines Ltd. American Depositary Shares
ONC
$37.4B
| $220K | 0.04% |
978
-10,122
| -91% | -$2.27M |
|
148
Tenax Therapeutics
TENX
$27.4M
| $216K | 0.04% |
+62,423
| New | +$216K |
|
149
Ventyx Biosciences
VTYX
$180M
| $214K | 0.03% |
97,955
+85,000
| +656% | +$185K |
|
150
Boston Scientific
BSX
$159B
| $210K | 0.03% |
+2,500
| New | +$210K |
|